Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-02-14
1997-01-07
Rose, Shep K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514777, 514891, 536 551, 5361231, A61K 3173, A61K 4736
Patent
active
055917240
ABSTRACT:
A method of treating interstitial cystitis comprising contacting the internal bladder and associated structures in a mammal having interstitial cystitis with a solution containing hyaluronic acid having a molecular weight of not less than approximately 2.times.10.sup.5 Daltons in a concentration effective to treat the interstitial cystitis.
REFERENCES:
patent: 4296104 (1981-10-01), Herschler
patent: 4302577 (1981-11-01), Rucker
patent: 4524066 (1985-06-01), Wolf
patent: 4640912 (1987-02-01), Hausman
patent: 4711780 (1987-12-01), Fahim
patent: 4820693 (1989-04-01), Gillespie
patent: 4879282 (1989-11-01), Saliba, Jr.
patent: 4966890 (1990-10-01), Gillespie
patent: 5037810 (1991-08-01), Saliba, Jr.
patent: 5180715 (1993-01-01), Parsons
patent: 5290271 (1994-03-01), Jernberg
patent: 5356883 (1994-10-01), Kuo et al.
Kiesewetter et al 2Eit. Urol. Nephrol. 58(10):735-738 (1965).
Gill et al J. Urol. 127(1):152-154 (1982).
Wakasuki et al J. Urol. 133(2): 319-323 (1985).
Holm-Bentzen et al Neurol. Urodyn. 5(6):519-523 (1986).
Hurst et al J. Urol. 138(2):433-437 (1987).
Maroudas et al Brit. J. Urol. 59(6):519-522 (1987).
Laurent et al Cell Tissue Res. 279(2):241-248 (1985).
Stewart et al., "The Use of Dimethyl Sulfoxide (DMSO) in the Treatment of Interstitial Cystitis," J. Urology, Vol. 98, pp. 671-672 (1968).
Strohmaier et al Helv. Chir. Acta 56(3):323-325 (1989).
Parsons et al., "Decreased Urinary Uronic Acid Levels in Individuals with Interstitial Cystitis," J. Urology, Vol. 143, pp. 690-693 (1990).
Fleischmann et al., "Clinical and Immunological Resonse to Nifedipine for the Treatment of Interstitial Cystitis," J. Urology, vol. 146, pp. 1235-1239 (1991).
Nickel et al., "The Bladder Mucus (Glycosaminoglycan) Layer in Interstitial Cystitis," J. Urology, vol. 149, pp. 716-718 (1993).
Hanno et al., "Conservative Therapy of Interstitial Cystitial," Seminars in Urology, vol. 9, No. 2, pp. 143-147 (1991).
Chelsky et al., "Bladder Permeability in Interstitial Cystitis is Similar to that of Normal Volunteers: Direct Measurement by Transvesical Absorption of 99m Technetiumdiethylenetriaminepentaacetic Acid," J. Urology, vol. 151, pp. 346-349 (1994).
Eldrup et al., "Permeability and Ultrastructure of Human Bladder Epithelium," Br. J. Urology, vol. 55, pp. 488-492 (1983).
Brandt, "The Effect of Synovial Hyaluronate on the Injestion of Monosodium Urate Crystals by Leukocytes," Clinica Chimica Acta, vol. 55, pp. 307-315 (1974).
Messing et al., "Interstitial Cystitis," Urology, vol. 12, No. 4, pp. 381-392 (1978).
Balazs et al., "The Effect of Hyaluronic Acid on Fibroblasts, Mononuclear Phagocytes and Lymphocytes," Biology of Fibroblasts, Academic Press, pp. 237-252 (1973).
Kuwahara et al., "Bacterial Infection and Acid Mucopolysaccharides in Epithelium of Rat Urinary Bladder," Urological Research, vol. 10, No. 2, pp. 93-96 (1982).
Alkemade Stanley J.
Morales Alvaro
Bioniche Inc.
Rose Shep K.
LandOfFree
Method for treating the urinary bladder and associated structure does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating the urinary bladder and associated structure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating the urinary bladder and associated structure will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1764235